Muck, I was so hoping this was heading toward 8 before the drop. You pegged it, I bow to you. I am thinking it came even earlier this year, market uncertainties notwithstanding. Well, that's it. I am going to work overtime all summer to double up in October. This way I can definitely sell half next April before the cycle repeats. I will finally take advantage of the swing and maintain my current position with less pain. From what we have seen not much will happen before then unless there is news the market just can't deny/interpret in their own twisted logic.
- Right now, the ARQL's market cap is ~$350M. - ARQL cash by this year-end is expected to be ~$120M and very low in-house expenses - In few months, ARQ 197 will be in Ph III trials for two cancers (HCC and NSCLC) - Asian Pharma market is as big as the North American market without a penny spending from ARQL. It is just pure royalties
There is no doubts that ARQL will be bought out as soon as any Ph III is successful for at no less than $3.5B+